PRESS RELEASE

06 March 2023 10:08:00 CET

INVITATION TO ASCELIA PHARMA INVESTOR UPDATE: BRINGING ORVIGLANCE TO MARKET – NEXT STEPS TOWARDS LAUNCH

Ascelia Pharma AB (publ) (ticker: ACE), hereby invites analysts, investors and media to its investor update on Tuesday March 14, 2023 at 14:00. Focus of the event will be on bringing Orviglance to market – next steps towards launch.

Live Q&A webcast
The event consists of presentations from Ascelia Pharma executives followed by a live Q&A webcast. The presentations will be available on Ascelia Pharma's website www.ascelia.com on March 14 at 08:00 a.m. CET.

The livestreamed Q&A webcast with will take place on March 14 from 14:00 CET. A recording of the Q&A webcast will be published on Ascelia Pharma's website after the event.

All presentations will be held in English.

Orviglance in focus
Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A pivotal clinical program of nine studies, including the global Phase 3 study SPARKLE, have been completed. Headline results from the Phase 3 study are expected mid-2023.

Registration for the live Q&A webcast
Participation for the live Q&A webcast can register by contacting Ascelia Pharma's Executive Assistant Delphine Biro at db@ascelia.com. Please confirm your participation no later than March 14, 2023.

Contacts

Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel: +46 735 179 118

Déspina Georgiadou Hedin, CFO and Investor Relations
Email: despina.georgiadou@ascelia.com
Tel: +46 765 697 873

This information was submitted for publication, through the agency of the contact persons set out above.

About Us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance (previously referred to as Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

About Orviglance (previously referred to as Mangoral)
Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A pivotal clinical program of nine studies, including the global Phase 3 study SPARKLE, have been completed.

About Oncoral
Oncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is now prepared for Phase 2 clinical development.

Attachments

INVITATION TO ASCELIA PHARMA INVESTOR UPDATE: BRINGING ORVIGLANCE TO MARKET – NEXT STEPS TOWARDS LAUNCH